LYEL Stock Analysis: Buy, Sell, or Hold?
LYEL - Lyell Immunopharma, Inc. Common Stock
$13.40
-0.93 (-6.49%)
▼
5d:
-15.78%
30d:
-2.33%
90d:
-45.97%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 11, 2026
26d
Get Alerted When LYEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: LYEL is down 15.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: LYEL is down 15.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: LYEL is currently trading at $13.40, which is considered fair relative to its 30-day fair value range of $12.33 to $14.51.
Technical Outlook: Technically, LYEL is in a strong downtrend. Immediate support is located at $12.41, while resistance sits at $16.80. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: LYEL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $37.17 (+177.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LYEL is in a strong downtrend. Immediate support is located at $12.41, while resistance sits at $16.80. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: LYEL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $37.17 (+177.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$12.33 -
$14.51
Company Quality Score
51/100
(HOLD)
Options IV Signal
54th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
79.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 54th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.5%)
- BULLISH: Trading 177.4% below Wall St target ($37.17)
- WARNING: Recommendation downgraded due to -15.8% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$12.33 -
$14.51
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$3.26
(24.3%)
Support & Resistance Levels
Support Level
$12.41
Resistance Level
$16.80
Current Trend
Strong Downtrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.68
Wall Street Target
$37.17
(+177.4%)
Revenue Growth (YoY)
-71.4%
Share & Embed Analysis
Last updated: July 15, 2026 3:20 AM ET
Data refreshes hourly during market hours. Next update: 4:20 AM
Data refreshes hourly during market hours. Next update: 4:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Lynn Seely
SELL
7455 shares
2026-02-11
Stephen J Hill
SELL
1236 shares
2026-02-11
Gary K Lee
SELL
1671 shares
2026-02-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 59 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
